Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia

(2016) Yoseph C. Elala et al.   AMERICAN JOURNAL OF HEMATOLOGY

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

(2015) R. S. Komrokji et al.   BLOOD

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis

(2015) C. Marty et al.   BLOOD

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

(2015) A. M. Vannucchi et al.   HAEMATOLOGICA

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms

(2015) D Pietra et al.   LEUKEMIA

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis

(2015) P Guglielmelli et al.   Blood Cancer Journal

Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors

(2015) S Cerquozzi et al.   Blood Cancer Journal

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

(2015) A. M. Vannucchi et al.   HAEMATOLOGICA

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

(2015) Animesh Pardanani et al.   JAMA Oncology

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

(2014) E. Rumi et al.   BLOOD

The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants

(2014) A. Tefferi et al.   BLOOD

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

(2014) P. Guglielmelli et al.   BLOOD

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

(2014) P. Lundberg et al.   BLOOD

A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients

(2014) Emnet Wassie et al.   BRITISH JOURNAL OF HAEMATOLOGY

The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis

(2014) J.-C. Hernandez-Boluda et al.   HAEMATOLOGICA

Calreticulin mutations in Chinese with primary myelofibrosis

(2014) B. Li et al.   HAEMATOLOGICA

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

(2014) A Tefferi et al.   LEUKEMIA

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

(2014) A Tefferi et al.   LEUKEMIA

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution

(2014) X Cabagnols et al.   LEUKEMIA

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

(2014) P Guglielmelli et al.   LEUKEMIA

Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact

(2014) A Tefferi et al.   LEUKEMIA

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

(2013) F. Cervantes et al.   BLOOD

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

(2013) G. Rotunno et al.   BLOOD

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

(2013) E. Rumi et al.   BLOOD

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis

(2013) Srdan Verstovsek et al.   BRITISH JOURNAL OF HAEMATOLOGY

Mutations and prognosis in primary myelofibrosis

(2013) A M Vannucchi et al.   LEUKEMIA

SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival

(2012) T. L. Lasho et al.   BLOOD

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

EZH2 mutational status predicts poor survival in myelofibrosis

(2011) P. Guglielmelli et al.   BLOOD

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

(2011) A Tefferi et al.   LEUKEMIA

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

(2010) F Passamonti et al.   LEUKEMIA

JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy

(2010) Richard T. Silver et al.   LEUKEMIA RESEARCH

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

(2008) A. M. Vannucchi et al.   BLOOD

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD